Download Free Medical Assessing and Managing Medicine Safety PowerPoint Presentation

Assessing and Managing Medicine Safety PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Adverse Drug Events, which is titled "Assessing and Managing Medicine Safety", to know about adverse drug reactions (ADRs), and medication and prescribing errors. Also understand the principles of medicine safety evaluation, management of spontaneous case reports of ADRs and medication and prescribing errors, and the process of monitoring, evaluating, and preventing ADRs and adverse drug events.

Tags : Adverse Drug Events, Medicine Safety, ADRs, medication, prescribing errors, evaluation, management

Published on : Jul 20, 2021 | Views : 1794 | Downloads : 5

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

1 Drug and Therapeutics Committee Session 4. Assessing and Managing Medicine Safety
Slide 2-

Objectives Describe the significance of— Adverse drug reactions (ADRs) Medication and prescribing errors Understand— Principles of medicine safety evaluation Management of spontaneous case reports of ADRs and medication and prescribing errors The process of monitoring, evaluating, and preventing ADRs and adverse drug events
Slide 3-

Outline Key Definitions Introduction ADRs—Pre- and postmarketing surveillance Causality Implications for the DTC Adverse Drug Events and Medication Errors Activities Summary
Slide 4-

Key Definitions (1) Adverse drug reaction (ADR) A noxious and unintended response to a medicine that occurs at normal therapeutic doses used in humans for prophylaxis, diagnosis, or therapy of disease, or for the modification of physiologic function The word “effect” is used interchangeably with “reaction.” Side effect Any unintended effect of a pharmaceutical product occurring at normal therapeutic doses and is related to its pharmacological properties. Such effects may be well-known and even expected and require little or no change in patient management. Serious adverse effect Any untoward medical occurrence that occurs at any dose and results in death, requires hospital admission or prolonged hospital stay, results in persistent or significant disability, or is life threatening
Slide 5-

Key Definitions (2) Adverse drug event Any untoward medical occurrence that may be present during treatment with a medicine but does not necessarily have a causal relationship with this treatment. Adverse drug events include medication errors and overdoses. Causality The probability that a particular medicine is responsible for an isolated effect or ADR. Signal Reported information on a possible causal relationship between and adverse event and a medicine, the relationship being previously unknown or incompletely documented. Usually more than one signal report is required to generate a signal, depending on the seriousness of the event and the quality of the information.
Slide 6-

Key Definitions (3) Prescribing error Incorrect medicine ordering by a prescriber Medication error Administration of a medicine or dose that differs from the written order Negligence Medical decision making or care below the accepted standards of practice
Slide 7-

Introduction ADRs and events constitute a serious problem increasing morbidity and mortality and health care costs worldwide. Overall incidence of ADRs in hospitalized patients in the United States in 1998 was 6.7%, and fatalities were 0.32%. Lazarou, J., B. H. Pomeranz, and P.N. Corey. 1998. Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-analysis of Prospective Studies. JAMA 279 (15):120–25. ADRs resulted in approximately 250,000 admissions a year in the United Kingdom Projected costs of ADRs to the United Kingdom’s National Health Service was £466 million (€ 680 million; USD 870 million) Hitchen, L. 2006. Adverse Drug Reactions Result in 250 000 UK Admissions a Year BMJ 332:1109 Pirmohamed, M. et al. 2004. Adverse Drug Reactions as Cause of Admission to Hospital: Prospective Analysis of 18,820 Patients. BMJ 329:15–19.
Slide 8-

Adverse Drug Reactions (1) Patient injury caused by a medicine taken in therapeutic doses Type A—Exaggerated pharmacological response Pharmacodynamic (e.g., bronchospasm from beta-blockers) Toxic (e.g., deafness from aminoglycoside overdose) Type B—Nonpharmacological, often allergic, response Medicine-induced diseases (e.g., antibiotic-associated colitis) Allergic reactions (e.g., penicillin anaphylaxis) Idiosyncratic reactions (e.g., aplastic anemia with chloramphenicol)
Slide 9-

Adverse Drug Reactions (2) Type C—Continuous or long term (time related) Osteoporosis with oral steroids Type D—Delayed (lag time) Teratogenic effects with anticonvulsants or lisinopril Type E—Ending of use (withdrawal) Withdrawal syndrome with benzodiazepines Type F—Failure of efficacy (no response) Resistance to antimicrobials
Slide 10-

Determining Medicine Safety: Identifying and Managing ADRs Premarketing clinical trials Animal studies, human studies—Phases I, II, III Cannot identify ADRs with incidence < 1% Unproven ADRs listing for legal protection of manufacturer Postmarketing surveillance Spontaneous reporting Postmarketing clinical trials—Phase IV Other methods—observational studies, meta-analysis, case reports Determining causality Actions taken to manage new ADRs
Slide 11-

Postmarketing Surveillance of ADRs:Spontaneous Reports Best method for detecting new ADRs Necessary because many ADRs not detected in pre- or postmarketing studies Initiated by physicians, pharmacists, nurses, patients Problems include underreporting, inaccurate reporting that may not show causality, and high false positive rates
Slide 12-

Postmarketing Surveillance of ADRs:Clinical Studies Postmarketing clinical studies Done to determine efficacy and safety (Phase IV trials) Generally poor in detecting ADRs because— RCTs often insufficient for assessing ADRs, so observational cohort and cases control studies are used Nonrepresentative patient selection Narrow medicine indications and dosing structure Limited concomitant medicine use
Slide 13-

Postmarketing Surveillance: Other Methods Observational studies provide limited identification of new ADRs Large databases in the United States and Europe from national health programs, HMOs, health insurance programs can provide data for case control or cohort studies Cohort studies useful for assigning causality Published case reports—provide limited information about ADRs Meta-analysis of published papers—provide identification of new ADRs by increasing the power of the clinical studies
Slide 14-

Actions for Newly Discovered ADRs “Dear Doctor” letters—describe a new safety concern about a particular medicine Package insert revisions For significant safety concerns Manufacturers must change the official labeling and the package insert to reflect the new safety concern Typically approved by the regulatory authority Medicine recalls (voluntary and compulsory) For serious safety concerns May be voluntary or imposed by the regulatory authority
Slide 15-

Determining Causality of an ADR Factors in determining causality Strength of the association Consistency of the observed evidence Temporality of the relationship ADR that occurs in association with a medicine does not mean the medicine is responsible Delayed reactions do not rule out the medicine as causing the ADR Dose-response relationship Confounding factors
Slide 16-

Classifying Causality of an ADR Certain causality—when a clinical event (including laboratory test abnormality) occurs in a plausible time relationship to medicine administration and cannot be explained by concurrent disease or other medicines or chemicals; re-administration of the medicine causes a similar reaction Probable or likely causality—when a clinical event occurs with a reasonable time sequence to medicine administration and is unlikely to be due to any concurrent disease or other medicine administration Possible causality—when a clinical event occurs with a reasonable time sequence to medicine administration, but which could be explained by concurrent disease or other medicine administration Unlikely causality—when a clinical event (including laboratory test abnormality) occurs in temporal relationship to medicine administration that makes a causal relationship improbable, and when other medicines, chemicals, or underlying disease provide plausible explanations
Slide 17-

Classifying Causality of an ADR: Naranjo Algorithm Total the score to determine the category of the reaction. The categories are defined as follows: Definite>9; Probable 5–8; Possible 1–4; Doubtful 0.
Slide 18-

Implications for DTC Surveillance of ADRs Monitoring and managing ADRs requires setting up surveillance systems Use of local surveillance (tracking and reporting) system run by the DTC Use of standardized reporting forms Analysis of reported ADRs to be done by selected DTC committee member Reporting of serious and recurring ADRs to regulatory authorities and manufacturers
Slide 19-

Process of reporting to higher facility and directly to national center Potential Role of DTC in ADR Reporting
Slide 20-

Managing ADRs Step 1. Evaluate the nature of the event. Obtain a detailed history of the patient. Identify and document the clinical reaction. Look up suspected medicines and known ADRs in the literature and match them with the reactions described by the patient Classify the severity of the reaction. Severe—fatal or life threatening Moderate—requires antidote, medical procedure, or hospitalization Mild—symptoms require discontinuation of therapy Incidental—mild symptoms; patient can chose whether to discontinue treatment or not
Slide 21-

Managing ADRs Step 2. Establish the cause. Use the Naranjo algorithm (or other system) to assess the patient’s reaction. Evaluate the quality of the medicine. Check for a medication error.
Slide 22-

Managing ADRs. Step 3. Take corrective and follow-up action. Corrective action will depend on cause and severity Severe ADRs Educate and monitor prescribers. Change the formulary or standard treatment guideline if necessary to substitute a medicine that is safer or that is easier to use by staff. Modify patient monitoring procedures. Notify drug regulatory authorities and manufacturers. All ADRs Educate and warn patients.
Slide 23-

Prevention of ADRs Schematic of preventable and unavoidable adverse events
Slide 24-

DTC's Role in Preventing ADRs Review ADR reports regularly and inform professional staff of the incidence and impact of ADRs in the region. Discuss changes in the formulary or standard treatment guidelines for significant or recurring problems with ADRs. Educate staff, especially providers, concerning ADRs. Identify medicines on the formulary that are “high risk” and should be monitored closely by physicians and pharmacists. Identify “high-risk” patient populations, including pregnant women, breast-feeding women, the elderly, children, and patients with renal or liver dysfunction; close monitoring of these patient populations by physicians and pharmacists will help prevent serious adverse reactions. Review medication errors and product quality complaints to ensure they are not contributing to the incidence of ADR at the hospital.
Slide 25-

Adverse Drug Events (1) An adverse drug event is any untoward medical occurrence that may be present during treatment with a medicine but does not necessarily have a causal relationship with this treatment. Adverse drug events include medication errors.
Slide 26-

Adverse Drug Events (2)* Record review of 15,000 inpatients in 1992 Adverse events 2.9% (30% due to negligence) 55% adverse events were non-operative; 19% were due to medicines 0.56% adverse drug events 35% drug adverse events due to negligence Primary medicines involved were antibiotics (25%), cardiovascular medicines (17%), analgesics (9%), and anticoagulants (9%) Types of medicine use error— Wrong medicine prescribed (21%) Prescribed despite known allergy (6%) Incorrect frequency (5%) Wrong dose (8%) Missed dose (5%) Medicine interaction (3%) *Thomas, E.J., D.M. Studdert, H.R. Burstin, et al. 2000. Incidence and Types of Adverse Events and Negligent Care in Utah and Colorado. Medical Care 38(3):261–271.
Slide 27-

Causes of Adverse Drug Events* Record review of 4,031 inpatients 247 (6.1%) adverse drug events; 70 (28%) preventable 194 (4.8%) additional errors without patient harm detected 264 errors were due to— Physician ordering (39%) Transcription (12%) Nurse administration (38%) Pharmacy dispensing (11%) Reasons for error included— Lack of prescriber knowledge (37%) Inadequate checking of medicine identity or dose (15%) Incomplete patient information (14%) Inaccurate transcription (11%) Failure to note medicine allergy information (9%) *Bates, D.W., D.J. Cullen, N. Laird, et al. 1995. Incidence of Adverse Drug Events and Potential Adverse Drug Events. Implications for Prevention. ADE Prevention Study Group. JAMA 274(1):29–34.
Slide 28-

Cost of Adverse Drug Events* Record review of 4,031 inpatients re-analyzed by case control Comparison controlling for level of care, severity, and co-morbidity (paired regression) 247 adverse drug events were estimated to have— Extended hospitalization by 2.2 days Increased cost of 3,244 U.S. dollars (USD) 70 adverse drug events due to errors were estimated to have— Extended hospitalization by 4.6 days Increased cost of USD 5,857 Bates, D.W., N. Spell, and D.J. Cullen. 1997. The Costs of Adverse Drug Events in Hospitalized Patients. ADS Study Group. JAMA 277(4):307–311.
Slide 29-

Medication Errors (1) Administration of medicine or dose that differs from written order Medicine prescribed but not given Administration of a medicine not prescribed Medicine given to the wrong patient Wrong medicine or IV fluid administered Wrong dose or strength given Wrong dosage form given
Slide 30-

Medication Errors (2) Medicine given for wrong duration Wrong preparation of a dose (e.g., incorrect dilution) Incorrect administration technique (e.g., unsterile injection) Medicine given to a patient with known allergy Wrong route of administration used Wrong time or frequency of administration
Slide 31-

Causes of Medication Errors Human factors Heavy staff workload and fatigue Inexperience, lack of training, poor handwriting, and oral orders Workplace factors Poor lighting, noise, interruptions, excessive workload Pharmaceutical factors Excessive prescribing Confusing medicine nomenclature, packaging, or labeling Increased number or quantity of medicines per patient Frequency and complexity of calculations needed to prescribe, dispense, or administer a medicine Lack of effective policies and procedures
Slide 32-

Medicine Ordering or Prescribing Transcribing Dispensing Administering Monitoring MEDICATION ERROR When Medication Errors Occur (1)
Slide 33-

Medicine Ordering or Prescribing Transcribing Dispensing Administering Monitoring MEDICATION ERROR 77.8% 5.8% 1.0% 12.8% 0.5% Fortescue E.B., et al. 2003. Prioritizing Strategies for Preventing Medication Errors and Adverse Drug Events in Pediatric Inpatients. Pediatrics 111:722–29. When Medication Errors Occur (2)
Slide 34-

Preventing Medication Errors (1) Establish consensus group of physicians, nurses, and pharmacists to select best practices Introduce a punishment-free system to collect and record information about medication-related errors Develop written procedures with guidelines and checklists for IV fluids and high-risk medicines (e.g., insulin, heparin, narcotics)
Slide 35-

Preventing Medication Errors (2) Require legible handwriting and complete spelling of medicine name Use standardized notation Doses given in mg, mcg, g Leading zero used for values < 1 and no trailing zero (e.g., 0.2 mg instead .2 mg; 2 mg instead of 2.0 mg) Write route of administration on all orders Write out directions completely (e.g., “daily” not “QD” or “OD”)
Slide 36-

Preventing Medication Errors (3) Limit use of telephone and oral orders to emergency situations Confirm identity of patients before administering medication Use standard administration times for hospitalized patients For look alike and sound alike names, establish a policy requiring that prescribers write both brand and generic names Use pharmacy staff to help prevent errors
Slide 37-

Using Pharmacists to Prevent Errors New York, USA* Pharmacists assigned to monitor medication orders Detected and corrected 2,103 significant errors during one year (4 errors/1,000 medication orders) Massachusetts, USA** Pharmacists assigned to make rounds with the intensive care unit team Made 366 recommendations on medicines; 362 accepted Reduction in preventable adverse drug events due to prescribing errors from 10.4 to 3.5 per 1,000 patient-days *Dean, B., M. Schachter, C. Vincent, et al. 1998. Causes of Prescribing Errors in Hospital Inpatients: a Prospective Study. Lancet 359 (9315):1373–78. **Leape, L.L., D.J. Cullen, M.D. Clapp, et al. Pharmacist Participation on Physician Rounds and Adverse Drug Events in the Intensive Care Unit. JAMA 282(3):267–70.
Slide 38-

Activities Activity 1 Case history: Penicillin Anaphylaxis Reported Activity 2 Case history: Acute Respiratory Infection in a Two-Year Old Activity 3 Serious ADRs with Phen-Fen Combination Medicine
Slide 39-

Summary (1) DTCs can contribute significantly to improved medicine safety by— Assessing the safety of all new medicines before placing on the formulary Implementing systems to monitor the occurrence of ADRs Managing and evaluating suspected ADRs, assigning causality, and taking corrective action when necessary
Slide 40-

Summary (2) Reporting ADRs to regulatory authorities and manufacturers Preventing the occurrence of ADRs and events by— ADR monitoring and reporting Careful evaluation of patients before prescribing, especially high-risk patients Educate staff